This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Next-generation BNP/NT-proBNP biosensors achieve femtogram-level detection using fluorescence, SERS, and nanozyme technologies, with smartphone-compatible readouts for point-of-care testing.
Why it matters
Current BNP testing requires hospital labs. Portable, ultra-sensitive biosensors could enable heart failure monitoring at home or in primary care.
The numbers in context
Detection limits at femtogram-to-picogram levels; technologies include FRET, quantum dots, SERS, nanozyme LFA, and ECL; smartphone-compatible designs.
How the study worked
Critical review of BNP/NT-proBNP detection technologies published 2020-2025.
Who was studied
N/A
What this study cannot tell us
Most technologies still in research phase. Clinical validation in real patient samples limited. Regulatory approval pathways long. Cost-effectiveness not assessed.
Read the original research
Toward next-generation BNP/NT-proBNP biosensors: multiplexed detection, biofouling control, and digital health integration.
Heart failure reviews, 31(1), 8
Citation
Rajendran, Jose Varghese; Elahi, Adnan; Scully, Patricia. (2025). Toward next-generation BNP/NT-proBNP biosensors: multiplexed detection, biofouling control, and digital health integration.. Heart failure reviews, 31(1), 8. https://doi.org/10.1007/s10741-025-10573-4